Computed tomography screening for the early detection of lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 6, 2006, Pages 591-594

  Petersen, Rebecca P ^a,b   Harpole Jr , David H ^a,b,c  

^a Duke University Medical Center ^*

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Durham Veteran's Administration Medical Center   (United States)

Author keywords

Computed tomography; Lung cancer; Screening

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LOW ENERGY RADIATION; LUNG CANCER; OVERALL SURVIVAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY;

EID: 33747588524     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0048     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the international staging system. J Thorac Cardiovasc Surg 1988;96:440-447.
3. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic analysis of stage I non small cell lung carcinoma of the lung. J Clin Oncol 1995;13:1265-1279.
4. Harpole DH Jr, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage 1 non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-56.
5. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA-Cancer J Clin 1997;47:5-27.
6. Fontana RS, Sanderson DR, Woolner LB, et al. Lung cancer screening: the Mayo program. J Occup Med 1986;28:746-750.
7. Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Chest 1984;86:44-53.
8. Henschke CI, Yankelevitz DF, Kostis WJ. CT screening for lung cancer. Semin Ultrasound CT MRI 2003;24:23-32.
9. Kaneko M, Eguchi K, Ohmatusu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
10. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002;20:911-920.
11. Sone S, Takahima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-1245.
12. Sone S, Li F, Yang Z-G, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001;84:25-32.
13. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
14. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 2001;92:153-159.
15. Henschke CI. Computed tomography screening for lung cancer: principles and results. Clin Cancer Res 2005;11[suppl 13]:4984-4987.
16. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
17. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 2004;350:351-360.
18. Strauss, GA, Herndon JE, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. [abstract]. Proc Am Soc Clin Oncol 2004; Abstract 7019.
19. Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10 [abstract]. Proc Am Soc Clin Oncol 2004; Abstract 7018.
20. Douillard J, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up [abstract]. J Clin Oncol 2005;23(suppl 16S):7013.
21. Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and non-solid nodules. AJR Am J Roentgenol 2002;178:1053-1057.
22. Henschke CI, I-ELCAP Investigators. CT screening tor lung cancer: update 2005. Surg Oncol Clin N Am 2005;14:761-776.
23. Jett JR. Limitations of screening for lung cancer with low-dose spiral computed tomography. Clin Cancer Res 2005;11[suppl 13]:4988-4992.
24. Wisnivesky JP, Mushlin AL, Sicherman N, et al. The cost-effectiveness of low-dose CT screening for lung cancer. Chest 2003;124:614-621.
25. Marshall D, Simpson KN, Earle CC, et al. Economic decision analysis model of screening for lung cancer. Eur J Cancer 2001;37:1759-1767.
26. Mahaderia P, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003;289:313-322.
27. Petricoin III EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
28. Jett JR, Midthun DE. Screening for lung cancer: current status and future directions. Chest 2004;125:158-162.